Trial of S-1 in Combination With Sorafenib for Patients With Advanced Hepatocellular Carcinoma
This study has been completed.
Information provided by (Responsible Party):
Samsung Medical Center
First received: May 25, 2010
Last updated: January 31, 2012
Last verified: January 2012
In preclinical studies, 5-fluorouracil, one of the active metabolites of S-1, showed synergistic effect to sorafenib in human colon carcinoma cell lines. Therefore, sorafenib combined with S-1 might be more effective treatment for patients with advanced HCC than sorafenib monotherapy. The investigators propose to conduct a phase I study to determine maximal tolerated dose (MTD) of S-1 in combination with fixed dose of sorafenib in patients with advanced HCC
Drug: sorafenib, TS-1
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
||Phase 1 Trial of S-1 in Combination With Sorafenib for Patients With Advanced Hepatocellular Carcinoma
Primary Outcome Measures:
- MTD [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
1. To determine maximal tolerated dose (MTD) of S-1 combined with fixed dose of sorafenib 400mg twice daily.
1. To evaluate toxicity profiles and dose-limiting toxicity (DLT)
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||September 2010 (Final data collection date for primary outcome measure)
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Patients with histologically confirmed hepatocellular carcinoma (HCC) or a combination of radiologically compatible finding to HCC, alpha-fetoprotein>400ng/mL and liver cirrhosis
Inoperable disease as defined by
- Localized disease in a portion of the liver that doses not allow the possibility of complete surgical removal of the tumor with a clear resection margin OR
- Presence of extra-hepatic disease OR
- Main portal vein or hepatic vein involvement (invasion or tumor thrombus) OR
- The HCC must not be amenable to intra-arterial therapy or local ablative therapy
- Minimum life expectancy of 12 weeks
- Age>18 years.
- ECOG Performance Status of 0-1
Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted within 7 days prior to screening:
- Hemoglobin>9.0 g/dl
- Absolute neutrophil count (ANC) >1,500/mm3
- Platelet count > 75,000/μl
- Total bilirubin < 1.5 times the upper limit of normal
- ALT and AST <5 x upper limit of normal
- Albumin >= 3g/dL
- PT-INR/PTT <1.5 x upper limit of normal
- Serum creatinine < 1.5 x upper limit of normal or Creatinine clearance >=50mL/min
- Signed and dated informed consent before the start of specific protocol procedures.
- Decompensated cirrhosis or stage C according to the Child-Pugh Classification
- Chemo-embolization within 8 weeks of inclusion
- Other concomitant anticancer agent, including Tamoxifen and Interferon
- History of cardiac disease: congestive heart failure >NYHA class 2; active CAD (MI more than 6 mo prior to study entry is allowed); cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin are permitted) or uncontrolled hypertension.
- History of HIV infection
- Active clinically serious infections (> grade 2 CTCAE version 3.0)
- Symptomatic metastatic brain or meningeal tumors
- Patients with seizure disorder requiring medication (such as steroids or anti-epileptics)
- History of organ allograft
- Patients with evidence or history of bleeding diathesis
- Patients undergoing renal dialysis
- Radiotherapy during study or within 4 weeks of start of study drug.
- Major surgery within 4 weeks of start of study
- Autologous bone marrow transplant or stem cell rescue within 4 months of study
- Prior exposure to the study drug.
- Pregnant or breast-feeding patients. Women of childbearing potential must have a negative pregnancy test performed within 7 days of the start of treatment. Both men and women enrolled in this trial must use adequate barrier birth control measures during the course of the trial (and men for at least 3 months after last administration of study medication).
- Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results
- Any condition that is unstable or could jeopardize the safety of the patient and their compliance in the study
- Patients unable to swallow oral medications.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01131689
|Samsung Medical Center
|Seoul, Korea, Republic of |
Samsung Medical Center
||Samsung Medical Center
History of Changes
|Other Study ID Numbers:
|Study First Received:
||May 25, 2010
||January 31, 2012
||Korea: Food and Drug Administration
Keywords provided by Samsung Medical Center:
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on May 26, 2016
Digestive System Diseases
Digestive System Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Molecular Mechanisms of Pharmacological Action
Protein Kinase Inhibitors